Literature DB >> 8045730

Soft tissue and visceral sarcomas in Irish patients. Interim analysis of data obtained by the Dublin Soft Tissue Tumour Panel.

E F Gaffney1, P A Dervan, M M McCabe, K Sheahan, E W Kay, M Leader, J Doyle, P A Daly, J J Fennelly, D N Carney.   

Abstract

The Dublin Soft Tissue Sarcoma Panel was established in 1989 with a view to achieving a unified approach to diagnosis and management of soft tissue and visceral sarcomas. This interim report presents data on 265 prospectively-evaluated patients and on a separate retrospective series of 126 patients. The patients in the prospective series were treated by 93 different surgical and medical specialists. Tumours presented in all anatomic sites and ranged in size from 0.2 to 60 cm. Leiomyosarcoma was the commonest tumour type. Eighty-nine tumours were inoperable at clinical presentation. There was a consensus panel diagnosis in over 90%, non-neoplastic reactive lesions and primitive round cell tumours being the most difficult cases diagnostically. Management, including onward referral for chemotherapy or radiation therapy, was inconsistent. The 2-year survival figures were: 43% (1989-91) and 37% (1980-88). These findings should provide a basis for the evaluation of coherent treatment strategies for Irish sarcoma patients.

Entities:  

Mesh:

Year:  1994        PMID: 8045730     DOI: 10.1007/bf02943260

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  27 in total

Review 1.  Future directions in the management of soft tissue sarcomas.

Authors:  A D Elias
Journal:  Hematol Oncol       Date:  1992 Jan-Feb       Impact factor: 5.271

2.  Soft tissue sarcomas. Imaging: an integrated approach.

Authors:  R Musumeci; L Balzarini; E Ceglia; R Petrillo; Y Reyner; J D Tesoro-Tess
Journal:  Ann Oncol       Date:  1992-04       Impact factor: 32.976

Review 3.  Progress in the recognition and treatment of soft tissue sarcomas.

Authors:  F R Eilber; J F Huth; J Mirra; G Rosen
Journal:  Cancer       Date:  1990-02-01       Impact factor: 6.860

4.  Pigmented ganglioneuroblastoma: a tumour cell 'storage disease'?

Authors:  G M O'Dowd; E F Gaffney
Journal:  Histopathology       Date:  1993-06       Impact factor: 5.087

5.  Surgical approach to soft tissue sarcomas of the extremities.

Authors:  G Pignatti; M Campanacci
Journal:  Ann Oncol       Date:  1992-04       Impact factor: 32.976

6.  Extremity soft tissue sarcomas: analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher-grade sarcomas.

Authors:  E E Lack; S M Steinberg; D E White; T Kinsella; E Glatstein; A E Chang; S A Rosenberg
Journal:  J Surg Oncol       Date:  1989-08       Impact factor: 3.454

Review 7.  Advances in the diagnosis and management of sarcomas.

Authors:  A D Elias
Journal:  Curr Opin Oncol       Date:  1992-08       Impact factor: 3.645

8.  Angiosarcoma arising from a defunctionalized arteriovenous fistula.

Authors:  M M Keane; D N Carney
Journal:  J Urol       Date:  1993-02       Impact factor: 7.450

9.  Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma.

Authors:  C D Fletcher
Journal:  Am J Surg Pathol       Date:  1992-03       Impact factor: 6.394

10.  Lucy Wortham James lecture. Multidisciplinary clinical investigation of the cancers of children. A model for the management of adults with cancer.

Authors:  G D Hammond
Journal:  Cancer       Date:  1985-03-15       Impact factor: 6.860

View more
  2 in total

1.  Processes and outcomes of care for soft tissue sarcoma of the extremities.

Authors:  Lawrence Paszat; Brian O'Sullivan; Robert Bell; Vivien Bramwell; Patti Groome; William Mackillop; Emma Bartfay; Eric Holowaty
Journal:  Sarcoma       Date:  2002

2.  Epidemiological study of soft-tissue sarcomas in Ireland.

Authors:  Nikita Bhatt; Sandra Deady; Amy Gillis; Alexia Bertuzzi; Aurelie Fabre; Eric Heffernan; Charles Gillham; Gary O'Toole; Paul F Ridgway
Journal:  Cancer Med       Date:  2015-11-21       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.